SUBSCRIBE 

© 2017 Biofortis Mérieux NutriSciences

ABOUT BIOFORTIS

As part of Mérieux NutriSciences, Biofortis supports the food and health industries by conducting research projects with a unique nutrition and analytical service. A one-stop shop CRO offering innovative services including clinical assessments, microbiota-related research, sensory evaluation and consumer studies.

FIND US ON

  • LinkedIn Biofortis Mérieux NutriSc.
  • Twitter Biofortis Mérieux NutriSc.
  • YouTube Biofortis Mérieux NutriSc.

3 Route de la Chatterie

44800 Saint-Herblain

FRANCE

Tel: +33 2 40 20 57 99

Poster: Fecal microbiota profile at diagnosis in the French IMODI cohort of breast cancer

June 21, 2019

Oumaïra Rahmouni (1), Steven Roblin (1), Yao Amouzou (1), Amandine Charreton (2), Patricia Lapierre (3), Séverine Tabone-Eglinger (2), Isabelle Treilleux (2), Olivier Tredan (2), Françoise Le Vacon (1), Sidonie N Lavergne (1)


(1) Biofortis Mérieux NutriSciences (Saint-Herblain, France), (2) Centre Léon-Bérard (Lyon, France), (3) Centre Georges-François Leclerc (Dijon, France).

 

This poster was presented on June 21st 2019 at Mibiogate's annual congress (Nantes, France). Another poster focused on the description of a cohort of patients with breast cancer will be presented at Cancéropôle Grand Ouest's next event on July 1st & 2nd 2019 (Tours, France).

 

 

 

Breast cancer (BC) is the most common cancer worldwide with approximately 2.1 million diagnoses in 2018. The etiology of BC remains elusive involving many interrelated factors such as genetic predispositions, environmental factors and lifestyle. 

 

The aim of this study was to investigate the fecal microbiota in localized BC patients at diagnosis. A total of 111 women with a primodiagnosis of localized BC were enrolled in 2 French referring hospitals from 2015 to 2018. Fecal microbiota V3-V4 regions of the 16S rRNA were sequenced using MiSeq System (Illumina) and the taxonomic classification was obtained using an in-house bioinformatic pipeline based on mothur software.

 

Relative abundance of bacteria (%), diversity (Shannon index) and richness (rarefied Chaos index) were established using Biofortis' in-house BioMan platform. Statistical analyses including demographic and clinical data were conducted using non-parametric tests with GraphPad.

 

This study lead to the following conclusions: in this cohort, fecal microbiota profiles varied based on BMI, clinical stage, and menopausal status. The potential interactions between microbiota, diet, and cancer treatments are under investigation.

 

To learn more about these results, or to ask for a copy of this poster, you may contact us on: biofortis-contact@mxns.com 


 

 

 

 

Share on Facebook
Share on Twitter
Share on LinkedIn
Share on Google+
Like this
Please reload

RECENT POSTS

Please reload

MICROBIOTA CASE STUDY

FOLLOW US

  • LinkedIn Biofortis Mérieux NutriSc.
  • Twitter Biofortis Mérieux NutriSc.
  • YouTube Biofortis Mérieux NutriSc.